OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
+13.45%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$625M
AUM Growth
+$625M
(+3.1%)
Cap. Flow
-$176M
Cap. Flow
% of AUM
-28.2%
Top 10 Holdings %
Top 10 Hldgs %
67.62%
Holding
50
New
6
Increased
8
Reduced
10
Closed
9
Top Buys
| 1 |
Nuvation Bio
NUVB
|
$26.9M |
| 2 |
Cogent Biosciences
COGT
|
$14.1M |
| 3 |
Corbus Pharmaceuticals
CRBP
|
$12.9M |
| 4 |
Pharvaris
PHVS
|
$11.5M |
| 5 |
Viridian Therapeutics
VRDN
|
$5.69M |
Top Sells
| 1 |
CYBN
Cybin
CYBN
|
$161M |
| 2 |
Dyne Therapeutics
DYN
|
$33M |
| 3 |
Insmed
INSM
|
$15.6M |
| 4 |
Terns Pharmaceuticals
TERN
|
$9.29M |
| 5 |
Praxis Precision Medicines
PRAX
|
$7.48M |
Sector Composition
| 1 | Healthcare | 99.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $86.7M | 13.49% | 3,006,980 +126,100 | +4% | +$3.64M |
|
|
VRNA
2
Verona Pharma
VRNA
$9.16B
| $52.8M | 8.21% | 1,835,200 -60,000 | -3% | -$1.73M |
|
3
Structure Therapeutics
GPCR
$1.11B
| $52.6M | 8.18% | 1,198,000 +57,940 | +5% | +$2.54M |
|
4
Dianthus Therapeutics
DNTH
$759M
| $47.8M | 7.44% | 1,746,667 | – | – |
|
5
ArriVent BioPharma
AVBP
$776M
| $46.4M | 7.22% | 1,976,387 +173,083 | +10% | +$4.07M |
|
|
CNTA
6
Centessa Pharmaceuticals
CNTA
$2.25B
| $32.2M | 5% | 2,012,052 -333,023 | -14% | -$5.33M |
|
|
7
Insmed
INSM
$28.8B
| $31.9M | 4.96% | 436,820 -213,396 | -33% | -$15.6M |
|
|
8
Nuvation Bio
NUVB
$1.02B
| $27.9M | 4.34% | 12,171,513 +11,739,913 | +2,720% | +$26.9M |
|
|
9
Corbus Pharmaceuticals
CRBP
$115M
| $23M | 3.58% | 1,115,000 +627,000 | +128% | +$12.9M |
|
10
Ocular Therapeutix
OCUL
$2.12B
| $21.1M | 3.28% | 2,425,000 | – | – |
|
|
11
Viridian Therapeutics
VRDN
$1.5B
| $19.8M | 3.08% | 870,000 +250,000 | +40% | +$5.69M |
|
12
Perspective Therapeutics
CATX
$250M
| $19M | 2.95% | 1,422,224 -158,025 | -10% | -$2.11M |
|
13
MindMed
MNMD
$676M
| $17.2M | 2.67% | 3,018,000 +865,000 | +40% | +$4.92M |
|
|
14
Cogent Biosciences
COGT
$1.69B
| $14.1M | 2.19% | +1,305,000 | New | +$14.1M |
|
15
BridgeBio Pharma
BBIO
$9.89B
| $14.1M | 2.19% | 552,000 -138,000 | -20% | -$3.51M |
|
|
16
Pharvaris
PHVS
$1.39B
| $11.5M | 1.79% | +620,470 | New | +$11.5M |
|
|
17
Dyne Therapeutics
DYN
$1.92B
| $9.44M | 1.47% | 262,726 -918,072 | -78% | -$33M |
|
18
Taysha Gene Therapies
TSHA
$797M
| $9.19M | 1.43% | 4,572,222 | – | – |
|
19
Gossamer Bio
GOSS
$562M
| $9.06M | 1.41% | 9,187,883 | – | – |
|
|
KLRS
20
Kalaris Therapeutics, Inc. Common Stock
KLRS
$76.3M
| $9.06M | 1.41% | 11,202,000 +1,402,000 | +14% | +$1.13M |
|
21
EyePoint Pharmaceuticals
EYPT
$797M
| $8.74M | 1.36% | 1,093,503 | – | – |
|
|
22
Praxis Precision Medicines
PRAX
$958M
| $7.48M | 1.16% | 130,000 -130,000 | -50% | -$7.48M |
|
23
Mineralys Therapeutics
MLYS
$1.03B
| $7.27M | 1.13% | 600,000 | – | – |
|
|
RGLS
24
DELISTED
Regulus Therapeutics
RGLS
| $6.69M | 1.04% | 4,263,701 | – | – |
|
25
Ventyx Biosciences
VTYX
$171M
| $5.21M | 0.81% | 2,391,114 | – | – |
|